CDK12 and neoplasm: By contrast, deletion and/or null mutations in CDK12 were reported in  ̃ 5% of prostate and ovarian cancer patients, where this genetic alteration is correlated with worse prognosis, thus indicating a putative tumour suppressor role for CDK12 in these cancers [155].